financetom
Business
financetom
/
Business
/
Top Premarket Decliners
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Top Premarket Decliners
Jul 24, 2024 5:06 AM

07:44 AM EDT, 07/24/2024 (MT Newswires) -- ATI Physical Therapy ( ATIP ) shares were down nearly 26% pre-bell Wednesday after Tuesday's 4.8% gain.

SAGE Therapeutics ( SAGE ) stock was more than 25% lower after the company said that a phase 2 trial of its treatment candidate for essential tremor did not exhibit a "statistically significant dose-response relationship" on the primary endpoint.

Verastem ( VSTM ) shares were down 24% after the company priced a $55 million securities offering.

Price: 4.55, Change: -1.58, Percent Change: -25.77

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Leafly Shares Dive After Nasdaq's Delisting Notice
Leafly Shares Dive After Nasdaq's Delisting Notice
Jan 16, 2025
02:17 PM EST, 01/16/2025 (MT Newswires) -- Leafly ( LFLY ) shares plunged about 50% in recent Thursday trading after the firm said the Nasdaq Hearings Panel determined to delist its shares from the exchange due partly to its failure to comply with net income listing requirement. Trading in shares and warrants will be suspended with the opening of trading...
Why Katapult Holdings (KPLT) Shares Are Up 63% Today
Why Katapult Holdings (KPLT) Shares Are Up 63% Today
Jan 16, 2025
Katapult Holdings Inc ( KPLT ) shares are trading higher by 63% to $11.41 during Thursday’s session after the company reported $75.2 million in gross originations for the fourth quarter of 2024, up 11.3% year-over-year and surpassing its November forecast of 6-8% growth. What To Know: Katapult ( KPLT ) says this marks the ninth consecutive quarter of annual growth...
New Analysis of Omeros' Narsoplimab to Treat Complications From Stem Cell Transplant Support Results
New Analysis of Omeros' Narsoplimab to Treat Complications From Stem Cell Transplant Support Results
Jan 16, 2025
02:17 PM EST, 01/16/2025 (MT Newswires) -- Omeros ( OMER ) said Thursday that results from a statistical analysis of narsoplimab, its monoclonal antibody to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy, or TA-TMA, showed robustness of the previously reported primary endpoint analysis. The company said that newly completed sensitivity analyses confirm the survival benefit of narsoplimab in patients with...
Issuer Direct to Be Renamed ACCESS Newswire, Change Ticker to ACCS
Issuer Direct to Be Renamed ACCESS Newswire, Change Ticker to ACCS
Jan 16, 2025
02:18 PM EST, 01/16/2025 (MT Newswires) -- Issuer Direct ( ISDR ) said Thursday it will change its name to ACCESS Newswire and trade under the new ticker ACCS on the NYSE American Exchange, effective Jan. 27. No action is required by stockholders with respect to the changes, the company said. Price: 9.00, Change: +0.14, Percent Change: +1.58 ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved